A Phase 3 interventional study of Rivaroxaban (Xarelto, BAY59-7939) and Enoxaparin followed by VKA in Venous Thrombosis, sponsored by Bayer. Completed at 324 sites in 34 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-02-27.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing rivaroxaban in Venous Thrombosis — 5 open to participants now, 6 under way, 2 of them phase 3. Rivaroxaban · Venous Thrombosis.
Among the 36 studies testing rivaroxaban in Venous Thrombosis, this one is the 5th largest by enrollment, is one of 2 that started in 2007, is one of 12 in phase 3, and was the 1st registered.
785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.
Browse Venous Thrombosis studies →5 of the 36 studies testing rivaroxaban in Venous Thrombosis are open now, in 6 countries. Recruiting first, the newest first:
Mayo Hospital Lahore · Sites in Pakistan
Ages 18–80
Prof. Stavros Konstantinides, MD · Sites in Austria, Germany
Ages 18–85
University Hospital, Angers · Sites in France
Ages 18+
Science Valley Research Institute · Sites in Brazil
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 18+
By country, each count listing its studies:
Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 13 · Phase 4 10
First in 2004; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,449 is above the median of 152 across 477 interventional studies indexed under Venous Thrombosis.
Median enrollment 120 across the 36 interventional studies. Of the 24 that completed or were terminated, 8 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 36 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
23 studies in Venous Thrombosis by Bayer: none open now, none under way, none of them phase 3. Of 23 finished, 6 (26%) have results posted.
Among the 23 studies in Venous Thrombosis by Bayer, this one is the 2nd largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2007, is one of 4 in phase 3, and was the 1st registered.
Bayer’s Venous Thrombosis studies by the year they started, since 2004.
3 of the studies testing rivaroxaban in Venous Thrombosis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06611319Phase 3Prof. Stavros Konstantinides, MDENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty | 2027-03 |
| NCT04694248First Affiliated Hospital of Zhejiang UniversityAnticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting | 2026-12-31 |
| NCT03129555Herlev and Gentofte HospitalThe Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE) | 2027-03-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 36 studies testing rivaroxaban in Venous Thrombosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bayer’s 23 in Venous Thrombosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, open-label, assessor-blind, event-driven, non-inferiority program for efficacy with a study treatment duration of 3, 6 or 12 months in patients with confirmed acute symptomatic DVT without symptomatic PE (Einstein-DVT).
Within the US 'Johnson \& Johnson Pharmaceutical Research \& Development, L.L.C.' is sponsor.
The treatment period was followed by an observational period of 30 days starting the day after the last intake of study medication, regardless of the actual duration of study drug administration. Participants who did not complete the treatment period also entered the observational period. It was also possible that participants did not enter the observational period, e.g. due to withdrawal of consent or termination of study participation. Participants who were transferring from study 11702 DVT (NCT00440193) to the extension study 11899 (NCT00439725) did not enter the observational period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants were to receive rivaroxaban 15 mg oral tablet twice daily for 3 weeks, followed by 20 mg once daily
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Participants were to receive 1.0 mg/kg enoxaparin twice daily (subcutaneous) for at least 5 days, plus vitamin K antagonist (VKA) (oral) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 to 3.0)
Drug: Enoxaparin followed by VKA
During the first 3 weeks patients will receive 15 mg rivaroxaban twice-daily. Thereafter, patients will receive rivaroxaban 20 mg once-daily. Rivaroxaban will be administered orally and should be taken with food.
Drug page: Enoxaparin
Enoxaparin 1.0 mg/kg twice daily with a minimal duration of 5 days. This 5 days treatment could include the period up to 36 h before randomization if enoxaparin twice-daily was used. VKA should be started as soon as possible but not later than 48 hours after randomization.
Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) Until the Intended End of Study Treatment
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries.
Time frame: 3-, 6- or 12-month study treatment period
Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE and All Cause Mortality Until the Intended End of Study Treatment
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries.
Time frame: 3-, 6- or 12-month study treatment period
Percentage of Participants With an Event for Net Clinical Benefit 1 Until the Intended End of Study Treatment
Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE, and major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries.
Time frame: 3-, 6- or 12-month study treatment period
Percentage of Participants With Recurrent DVT Until the Intended End of Study Treatment
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries.
Time frame: 3-, 6- or 12-month study treatment period
Percentage of Participants With Clinically Relevant Bleeding, Treatment-emergent (Time Window: Until 2 Days After Last Dose)
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Clinically relevant bleeding included major bleeding (overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death) and non-major bleeding associated with medical intervention, unscheduled physician contact, (temporary) cessation of study treatment, discomfort for the participants such as pain, or impairment of activities of daily life.
Time frame: 3-, 6- or 12-month study treatment period
Percentage of Participants With All Deaths
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either autopsy, results/films/images of confirmatory testing, and/or case summaries.
Time frame: 3-, 6- or 12-month study treatment period
Percentage of Participants With Other Vascular Events, On-treatment (Time Window: Until 1 Day After Last Dose)
All pre-defined vascular events (ST segment elevation myocardial infarction, non ST segment elevation myocardial infarction, unstable angina, ischemic stroke, transient ischemic attack, non-central nervous system systemic embolism or vascular death) were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based results/films/images of confirmatory testing, and/or case summaries.
Time frame: 3-, 6- or 12-month study treatment period
Percentage of Participants With the Individual Components of Efficacy Outcomes Until the Intended End of Study Treatment
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death.
Time frame: 3-, 6- or 12-month study treatment period
Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) During Observational Period
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), results/films/images of confirmatory testing, and/or case summaries.
Time frame: Up to 30 days after the last intake of study medication
Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE and All Cause Mortality During Observational Period
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries.
Time frame: Up to 30 days after the last intake of study medication
Percentage of Participants With an Event for Net Clinical Benefit 1 During Observational Period
Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE or major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries.
Time frame: Up to 30 days after the last intake of study medication
Percentage of Participants With Recurrent DVT During Observational Period
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries.
Time frame: Up to 30 days after the last intake of study medication
Percentage of Participants With the Individual Components of Efficacy Outcomes During Observational Period
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death.
Time frame: Up to 30 days after the last intake of study medication
Participants with confirmed acute proximal symptomatic deep vein thrombosis (DVT) without symptomatic pulmonary embolism (PE) were recruited at specialized study sites.
| Milestone | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| Started | 1731 | 1718 |
| Participants received treatment | 1718 | 1711 |
| Completed | 1426 | 1367 |
| Not completed | 305 | 351 |
| Withdrew: Adverse event | 74 | 67 |
| Withdrew: Death | 19 | 22 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Lost to follow-up | 12 | 18 |
| Withdrew: Physician decision | 3 | 6 |
| Withdrew: Protocol violation | 16 | 19 |
| Withdrew: Withdrawal by subject | 36 | 77 |
| Withdrew: Clinical endpoint reached | 28 | 25 |
| Withdrew: Study terminated by sponsor | 102 | 94 |
| Withdrew: Protocol driven decision point | 2 | 2 |
| Withdrew: Switch to commercial drug | 0 | 2 |
| Withdrew: Technical problems | 1 | 1 |
| Withdrew: Participant convenience | 5 | 2 |
| Withdrew: Participant did not receive treatment | 7 | 13 |
| Withdrew: Site closed by investigator | 0 | 2 |
| Milestone | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| Started | 1425 | 1407 |
| Completed | 1380 | 1369 |
| Not completed | 45 | 38 |
| Withdrew: Adverse event | 2 | 2 |
| Withdrew: Death | 15 | 20 |
| Withdrew: Lost to follow-up | 12 | 8 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Withdrawal by subject | 11 | 8 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Clinical endpoint reached | 1 | 0 |
| Withdrew: Participant convenience | 2 | 0 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) Until the Intended End of Study Treatment | 2.1 | 3.0 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE and All Cause Mortality Until the Intended End of Study Treatment | 4.0 | 5.1 |
Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE, and major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| Percentage of Participants With an Event for Net Clinical Benefit 1 Until the Intended End of Study Treatment | 2.9 | 4.2 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| Percentage of Participants With Recurrent DVT Until the Intended End of Study Treatment | 0.9 | 1.6 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Clinically relevant bleeding included major bleeding (overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death) and non-major bleeding associated with medical intervention, unscheduled physician contact, (temporary) cessation of study treatment, discomfort for the participants such as pain, or impairment of activities of daily life.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| Percentage of Participants With Clinically Relevant Bleeding, Treatment-emergent (Time Window: Until 2 Days After Last Dose) | 8.1 | 8.1 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either autopsy, results/films/images of confirmatory testing, and/or case summaries.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| All post-randomization | 2.4 | 3.0 |
| Treatment-emergent (time window: 2 days) | 1.0 | 1.1 |
| Treatment-emergent (time window: 7 days) | 1.2 | 1.5 |
All pre-defined vascular events (ST segment elevation myocardial infarction, non ST segment elevation myocardial infarction, unstable angina, ischemic stroke, transient ischemic attack, non-central nervous system systemic embolism or vascular death) were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based results/films/images of confirmatory testing, and/or case summaries.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| Percentage of Participants With Other Vascular Events, On-treatment (Time Window: Until 1 Day After Last Dose) | 0.7 | 0.8 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| Death (PE) | 0.06 | 0 |
| Death (PE cannot be excluded) | 0.2 | 0.3 |
| Symptomatic PE and DVT | 0.06 | 0 |
| Symptomatic recurrent PE only | 1.2 | 1.0 |
| Symptomatic recurrent DVT only | 0.8 | 1.6 |
| Death (bleeding) | 0.06 | 0.3 |
| Death (cardiovascular) | 0.1 | 0.2 |
| Death (other) | 1.8 | 2.0 |
| Major bleeding | 0.9 | 1.3 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), results/films/images of confirmatory testing, and/or case summaries.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) During Observational Period | 0.8 | 0.5 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE and All Cause Mortality During Observational Period | 2.2 | 1.8 |
Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE or major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| Percentage of Participants With an Event for Net Clinical Benefit 1 During Observational Period | 1.1 | 1.1 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| Percentage of Participants With Recurrent DVT During Observational Period | 0.6 | 0.3 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| Death (PE) | 0 | 0 |
| Death (PE cannot be excluded) | 0.07 | 0.07 |
| Symptomatic PE and DVT | 0 | 0 |
| Symptomatic recurrent PE only | 0.3 | 0.1 |
| Symptomatic recurrent DVT only | 0.6 | 0.3 |
| Death (bleeding) | 0.07 | 0.1 |
| Death (cardiovascular) | 0.07 | 0.3 |
| Death (other) | 1.3 | 0.8 |
| Major bleeding | 0.2 | 0.6 |
Net clinical benefit 2: composite of recurrent DVT or non-fatal or fatal PE, major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to transfusion of ≥2 units, occurring in a critical site or contributing to death, cardiovascular death, myocardial infarction, stroke, and non CNS (central nervous system) systemic embolism. Net clinical benefit was considered greater in those participants with fewer composite events. All events confirmed by independent committee blinded to treatment, based on compression ultrasound, venography, spiral CT scan, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy, results/films/images of confirmatory testing and/or case summaries
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| Percentage of Participants With an Event for Net Clinical Benefit 2 Until the Intended End of Study Treatment | 3.6 | 4.7 |
Net clinical benefit 2: composite of recurrent DVT or non-fatal or fatal PE, major bleeding, cardiovascular death, myocardial infarctions, stroke, or non CNS systemic embolism. Major bleeding was associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound (DVT), venography (DVT), spiral CT scanning (PE), pulmonary angiography ( PE), ventilation/perfusion lung scan (PE), lung scintigraphy (PE), autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| Percentage of Participants With an Event for Net Clinical Benefit 2 During Observational Period | 1.2 | 1.3 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | — | 222/1,718 (12.9%) | 241/1,718 (14%) |
| Enoxaparin/VKA | — | 252/1,711 (14.7%) | 212/1,711 (12.4%) |
| Event | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 11/1718 | 8/1711 |
| PneumoniaInfections and infestations | 5/1718 | 10/1711 |
| HaematuriaRenal and urinary disorders | 4/1718 | 8/1711 |
| SepsisInfections and infestations | 2/1718 | 7/1711 |
| Cervix carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/1718 | 7/1711 |
| Ischaemic strokeNervous system disorders | 4/1718 | 7/1711 |
| Alanine aminotransferase increasedInvestigations | 2/1718 | 6/1711 |
| International normalised ratio increasedInvestigations | 0/1718 | 5/1711 |
| Hepatic enzyme increasedInvestigations | 1/1718 | 5/1711 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/1718 | 5/1711 |
| Event | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| NasopharyngitisInfections and infestations | 100/1718 | 91/1711 |
| HeadacheNervous system disorders | 91/1718 | 70/1711 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 90/1718 | 74/1711 |
| Age, Continuous(years) | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA | Total |
|---|---|---|---|
| Mean | 55.8 ± 16.4 | 56.4 ± 16.3 | 56.1 ± 16.4 |
| Age, Customized(participants) | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA | Total |
|---|---|---|---|
| 18 - < 40 years | 314 | 279 | 593 |
| 40 - < 60 years | 642 | 662 | 1304 |
| 60 - < 75 years | 530 | 519 | 1049 |
| ≥ 75 years | 245 | 258 | 503 |
| Sex: Female, Male(Participants) | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA | Total |
|---|---|---|---|
| Female | 738 | 751 | 1489 |
| Male | 993 | 967 | 1960 |
Showing the first 100 of 324 sites across 34 countries. Choose a country and city above to see the rest.
The record gives a start of Mar 2007, a primary completion of Apr 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2013, 2 years 9 months after primary completion. A results delay was requested in Dec 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rivaroxaban